Plasmid DNA (pDNA) CDMO Services

Plasmid DNA CDMO Services — Precision by Design

Elise Biopharma treats plasmid DNA as a regulated manufacturing asset, not a lab consumable. Our platform brings together strain engineering, controlled fed-batch fermentation, and alkaline lysis executed by data—not by habit. Orthogonal chromatography clears liabilities with intention, while an integrated analytics suite tells the same truth in development and GMP.

Sponsors turn to us when plasmid quality limits the speed of mRNA, AAV, lentiviral, CRISPR, or DNA vaccine programs. They come because our documentation reads like an engineered control story, not an experiment report.

Our Plasmid DNA CDMO Services are built around a few non-negotiables:

• A supercoiled fraction that holds through long holds.
• Endotoxin levels low by design—not disguised by chemistry.
• Residual host DNA and RNA driven to single-digit parts per million.
• A release panel so transparent that any reviewer can reproduce it without chasing vendors.

The economics are explicit, the risk ledger written on day one, and the comparability plan in place before the first change request arrives.

Phase-Appropriate Manufacturing Grades

Every plasmid journey begins at a different stage, so Elise Biopharma built a modular production architecture to match every milestone—from early discovery to commercial GMP release. Each grade uses the same control philosophy and analytical backbone, making transitions seamless and regulator-friendly.

Research-Grade (R&D):
Rapid plasmid prototyping for discovery, assay development, and proof-of-concept studies. Run under the same design logic and analytics used later in GMP to ensure data continuity.

HQ (High-Quality / Pre-GMP):
A faster, cost-effective grade that mirrors GMP processes and documentation without full regulatory overhead. Designed for IND-enabling toxicology or process comparability batches.

GMP-Grade:
Manufactured in ISO-classified suites under full GMP control with ALCOA+ data integrity, digital batch records, and validated analytical methods. Suitable for IND/IMPD filings, clinical manufacturing, and commercial production.

Commercial Supply:
Large-scale production up to multi-kilogram campaigns with long-term stability programs, process characterization, and lifecycle comparability management under ICH Q12.

Each grade scales within a unified design space—no new learning curves, no analytical drift, no revalidation loops. The same digital twin, the same physics, the same data logic—simply tuned for scope and regulation. That’s how Elise Biopharma’s Plasmid DNA CDMO Services maintain control from idea to approval.

Defining the Product

We start by defining exactly what the plasmid must be. The backbone and insert size, origin of replication, copy-number control, and selection system (antibiotic or antibiotic-free) are locked early. Transcriptional elements and sequence audit trails are verified with automated traceability tools.

Plasmid Design & Optimization Suite

Every strong plasmid starts in silico. Elise Biopharma’s Plasmid Design & Optimization Suite integrates computational biology, synthetic design rules, and manufacturability modeling to ensure every construct behaves predictably from sequence to GMP production.

We use proprietary software and AI-assisted bioinformatics to refine vector architecture before it ever reaches the fermentor:

• Sequence optimization: Codon harmonization, secondary-structure prediction, and GC-content modeling for stable replication and minimal truncation risk.
• Origin & backbone tuning: Selection of origins (ColE1, pUC, pBR, RK2, or custom) matched to target copy number, host metabolic burden, and downstream viscosity management.
• Antibiotic-free systems: Design of operator/repressor modules or auxotrophic complementation circuits that comply with regulatory guidance for antibiotic-free plasmid production.
• Manufacturability simulation: Computational analysis of restriction sites, repeats, inverted sequences, and recombination hotspots to prevent cloning artifacts and propagation failures.
• Digital version control: Each design iteration is logged through an ALCOA+ compliant audit trail, linking in-silico sequence files directly to wet-lab execution.

When clients share a genetic map, Elise doesn’t simply synthesize it—we re-engineer it for scalability, predictability, and regulatory elegance. The result is a plasmid that grows cleanly, purifies without drama, and passes analytical review on the first attempt.

This front-end investment shortens development cycles and eliminates the “mystery variance” that haunts conventional plasmid suppliers. At Elise, design is not just pre-production—it’s the first act of process control.

Host selection follows logic, not tradition. We favor E. coli K-12 lineages with ΔendA/ΔrecA backgrounds for stability. Growth and feed strategies are engineered to prevent chromosomal DNA release. Lysis and neutralization follow a validated choreography that respects physics at scale.

Purification uses anion-exchange capture followed by orthogonal polishing. If we employ enzymes such as RNase, they come with validated clearance and residual-testing data, not good intentions. Digital twins and PAT ensure every timing and setpoint decision has a reason. All choices are captured in eBR/MES records with full ALCOA+ traceability, allowing inspectors to follow the batch without guesswork.

This is the rhythm of our Plasmid DNA CDMO Services: short feedback loops, transparent trade-offs, and dossiers that eliminate ambiguity rather than bury it in jargon.

Cell Banking & Archiving Services

Every plasmid program relies on a stable biological origin. Elise Biopharma’s Cell Banking & Archiving Services secure that foundation by establishing master and working banks that are fully characterized, traceable, and compliant with global GMP expectations.

Our process begins with qualified E. coli K-12 derivatives, engineered for genetic stability and low endotoxin production. Each strain undergoes a standardized cell-banking protocol that combines controlled cryopreservation, digital genealogy, and environmental segregation.

• Master Cell Bank (MCB): Generated from a single, authenticated clone and expanded under cGMP. Each MCB is tested for identity, plasmid retention, viability, purity, and absence of bacteriophage or contaminant species.
• Working Cell Bank (WCB): Derived directly from the MCB, used for production campaigns to preserve genetic consistency and batch lineage integrity.
• Characterization suite: Includes 16S rRNA sequencing, plasmid restriction mapping, antibiotic sensitivity panels, and stability tracking under accelerated and long-term storage.
• Cryostorage and monitoring: Dual-site LN₂ vapor-phase freezers with continuous telemetry, redundant alarms, and chain-of-custody logging integrated with our eBR/MES platform.
• Digital genealogy: Every vial carries a barcode tied to its full production and analytics record, allowing instant trace-back during audits or regulatory review.

Cell banks are periodically retested to confirm plasmid maintenance and expression consistency. When a client’s regulatory filing references Elise Biopharma’s banks, they reference continuity—not just compliance.

For multi-product clients, Elise also maintains long-term archival banks under Q12 lifecycle frameworks, enabling reproducible re-initiation of legacy programs or comparability bridging across generations.

This layer of infrastructure transforms cell banking from a procedural requirement into a strategic asset. At Elise Biopharma, every future batch begins with a bank that already understands the process.

Program Architecture and Control Narrative

A plasmid program that scales reads like a well-written investment memo—assumptions clear, levers explicit, and downside contained.

We begin with a Quality Target Product Profile (QTPP) that mirrors the plasmid’s purpose. Whether it serves as an IVT template for mRNA, a helper or packaging cassette for AAV and LVV, a donor template for genome editing, or an API for DNA vaccines, the QTPP defines the goal.

From that truth, Critical Quality Attributes (CQAs) follow naturally:

• Sequence identity and confirmation
• Supercoiled percentage and topology (sc/oc/linear)
• Residual host DNA, RNA, and protein
• Endotoxin and residual antibiotic content
• Salt, solvent, and detergent profiles
• Phase-appropriate bioburden and sterility
• Stability through storage and handling

Each CQA connects directly to Critical Process Parameters (CPPs) that truly move quality. Feed rate, specific growth, lysis timing, and energy input are measured and mapped. Neutralization pH and temperature, nuclease strategy, capture conductivity, polishing selectivity, and UF/DF shear parameters are validated before scale.

Engineering Discipline, Not Guesswork

We test processes deliberately, not through hope. Compact designs of experiments define the workable range for growth, lysis, filterability, and resin capacity—and the boundaries that cause viscosity spikes or topology breaks.

Scale-down models match impeller design, power-per-volume, and gas flow. If a reactor fails to reproduce oxygen or heat transfer faithfully, it is not a model—it’s theater. Engineering runs verify these limits under real conditions while eBR/MES captures every sensor decision.

Once the ranges hold, we freeze the control strategy and move into formal characterization with edge-of-failure runs. The Module 3 narrative evolves in parallel so the documentation stays synchronized with the real process.

The Elise Cadence

When clients ask what sets Elise apart in Plasmid DNA CDMO Services, the answer is rhythm:

• Define truth early.
• Measure only what moves it.
• Write the regulatory story while the process comes to life.

This approach replaces uncertainty with evidence and converts molecular ambition into regulatory confidence—exactly what modern biologics manufacturing demands.

Upstream: Strain, Copy Number, and Fed-Batch Control

Hosts are chosen for plasmid stability and low background nuclease: K-12 derivatives (e.g., DH10B, W3110, MG1655 variants) with ΔendA/ΔrecA backgrounds are our default. Copy number is not maximized blindly; we balance burden against downstream viscosity, growth against oxygen and heat limits, and footprint against COGS. Selection systems follow the file philosophy: antibiotic-based selection where appropriate, or antibiotic-free systems (auxotrophy, operator–repressor, toxin–antitoxin) when regulatory preference or downstream product positioning argues for it. Origins (ColE1-like, pMB1 derivatives, or defined low/medium-copy systems) are chosen with the stability envelope in mind; runaway replication may look attractive until viscosity and lysis risks erase gains.

Media and feed are designed to support stable specific growth rate (µ) below overflow cliffs while preserving ribosome bandwidth for plasmid maintenance. Raman or FTIR chemometrics infer extracellular glucose and acetate; off-gas mass spectrometry provides OUR/CTR and RQ; capacitance is used where relevant to watch viable volume. A multivariable controller coordinates feed, agitation, and back-pressure to hold oxygen transfer without headspace oscillations that upset pH and DO loops. Temperature and pH policies are not copied from a paper; they are tuned to minimize lysis and to keep topology stable in later steps. Antifoam is treated as a chemistry problem with downstream consequences; we validate resin compatibility under realistic exposure rather than assuming.

The upstream acceptance test is simple: biomass in the target band, negligible lysis by surrogate markers, predictable filterability, and a lysate that behaves the same way Tuesday as it did last month. That consistency is what makes the rest of Plasmid DNA (pDNA) CDMO Services look easy.

Harvest, Alkaline Lysis, and Neutralization

Timing ruins or preserves plasmid. We harvest when capacitance slope and off-gas inflections indicate we have the mass to meet the campaign’s grams but before endogenous nuclease and autolysis push chromosomal DNA into the pool. Disc-stack centrifugation or microfiltration clarifies the broth with shear budgets that our twin can explain; the goal is low breakage and a pellet or retentate that lyses cleanly.

Alkaline lysis is a choreography, not a ritual. NaOH/SDS concentrations, addition order, mixing energy, and time are controlled by data. Inline or at-line conductivity and UV cues confirm lysis and guide neutralization cadence. We avoid shear during neutralization to prevent chromosomal DNA shredding; temperature is held in a narrow window because viscosity and precipitation kinetics are sensitive. If an enzymatic RNA reduction is used, it is used early and cleared deliberately; if we run RNase-free, we deploy selective precipitation and chromatographic strategies that give the same result without introducing new liabilities. The success condition is unromantic: a neutralized lysate with intact supercoiled topology and viscosity and solids profiles that a filtration train can respect.

Clarification and Primary Purification

Primary clarification is dimensioned with measured filterability indices across realistic solids loads; staged depth filtration strategies are validated on development lots before GMP. Nuclease treatment to remove residual DNA is executed with validation for clearance in downstream steps and for absence at release. The first chromatographic capture is typically anion exchange in bind/elute or flow-through mode depending on sequence content and ionic behavior; we choose pH and conductivity windows that produce robust binding, clean breakthrough, and elution that does not punish topology. Conductivity and UV trajectories are simulated in advance so an operator is never asked to fix physics in real time.

If a legacy process uses CTAB or other phase-separation approaches, we convert to industrially robust trains unless the dossier obligates the chemistry; when we must keep legacy steps, we write and validate the clearance and cleaning logic rather than insisting it is fine because it worked once. The point is constant: Plasmid DNA (pDNA) CDMO Services here prefer orthogonal, predictable operations that do not surprise a regulator or a scheduler.

Polishing, RNA and Protein Clearance, Endotoxin by Design

Polish right, and the release panel becomes routine. Mixed-mode resins, hydrophobic interaction, and high-resolution AEX are used as needed to separate RNA, protein, and topology variants. Where enzymatic RNA removal is part of the design, we prove residual clearance and backstop with orthogonal analytics; where we avoid RNase, we apply LiCl or selective precipitation logic and resins that target RNA’s behavior under tuned conductivity and pH. Host-cell protein is cleared with a combination of ion-exchange selectivity and wash steps designed around the lysate’s real hydropathic profile; we do not pretend that one wash fits all.

Endotoxin is controlled upstream and polished downstream. We reduce LPS ingress with host choice, growth policy, and gentle harvest/lysis; we then employ AEX flow-through or tuned bind/elute steps that truly remove endotoxin rather than simulate clearance through LER artifacts. If a formulation risks LER, we document it and verify with orthogonal biological activity checks. Our bias is detergent-light and surfactant-aware; we do not borrow clearance from chemistries that will later confuse analytics or spoil resin performance. The upshot for Plasmid DNA CDMO Services is acceptance ranges for endotoxin that are aggressive because the process deserves them, not because the paper looks better that way.

UF/DF is sized for shear and adsorption; membrane chemistry is screened against plasmid binding and topology conversion. Diafiltration paths are simulated to maintain ionic strength and pH corridors that protect supercoiled fraction. We avoid dead-legs and interfacial conditions that invite nicking. The resulting bulk is a plasmid that behaves like a controlled material: topology in range, impurities where the file said they would be, and a viscosity the plant can move.

Grade Definitions and Spec Philosophy

We run three coherent grades under one quality philosophy so sponsors can move between them without re-learning the molecule.

• Research grade: rapid supply for screening and non-GLP studies. Identity by restriction mapping/sequence checks, supercoiled fraction in a pragmatic range, residuals controlled for science rather than filing.
• IVT-grade (mRNA input): supercoiled fraction and residual DNA/RNA tailored to linearization and transcription; endotoxin ≤ 0.01 EU/µg typical; RNase-aware handling; residual solvents/salts to IVT-compatible limits; robust A260/280 with sequence-verified template.
• GMP therapeutic grade (DMF-referenced): full Module 3-ready characterization; identity, topology distribution, residuals (HCP/DNA/RNA, solvents, detergents), endotoxin, bioburden/sterility as phase-appropriate, stability, and comparability hooks. Batch genealogies readable by QA without decoding.

We do not advertise miracle specs that only exist at four liters on a sunny day. We post acceptance ranges the plant can meet in February and in August, and the dossier explains why those numbers were chosen. That is the difference between Plasmid DNA (pDNA) CDMO Services that close and programs that chase a slide.

Analytics and Release

Identity is confirmed by restriction mapping with sequencing-adjacent checks on critical junctions; for GMP, we expand to full sequencing coverage appropriate to risk. Topology distribution is quantified by validated HPLC (e.g., anion-exchange or CEC) and confirmed by orthogonal gel-based methods; we report supercoiled, open circular, and linear fractions, not just a headline percentage. Residual host DNA is measured by qPCR with a limit of quantitation that aligns to downstream use (IVT vs therapeutic); RNA by RiboGreen or orthogonal assays when RNase-free designs are used; HCP by E. coli-specific ELISAs or LC-MS fingerprints when the panel requires it. Endotoxin is measured by kinetic chromogenic methods with spike-recovery panels and, when warranted, biological orthogonals so LER does not mislead. Residual solvents and detergents are reported with GC/HPLC per validated methods; conductivity/osmolality/pH guardrails are documented. Bioburden and sterility expectations are phase-tuned, with environmental monitoring narratives that an inspector can read without a translator.

Method lifecycle follows ICH Q2(R2): qualification during learning, validation when locking, system suitability and bracketing for day-to-day truth. The analytics matrix is finalized early so development and GMP read the same. We do not change rulers mid-program.

Digital Twins, PAT, and Data Integrity

The plasmid twin combines mechanistic balances for oxygen, heat, and mixing with learned shells that capture plant behavior. It reads Raman/FTIR, off-gas mass spectrometry, capacitance, torque, and pressure signals; it recommends setpoint moves with bounded uncertainty and provides residual-based alarms when the world stops matching its training. Lysis and neutralization are timed by inline conductivity and UV with twin-assisted thresholds; if an operator needs to decide by feel, the model is not finished. Chromatography cycles are interpreted by pressure/UV/conductivity signatures to forecast binding capacity and breakthrough; UF/DF loops are run under pressure and shear budgets enforced by the control system. eBR/MES carries the story in ALCOA+ form: why a feed was reduced, what uncertainty was assumed, and how those choices link to release. We do not say “digital” unless it prevents deviations, shortens reviews, or saves money you can measure.

Formulation, Bulk Handling, and Stability

Bulk plasmid is formulated for the job ahead. IVT-grade material favors low-salt buffers that do not complicate linearization or transcription; GMP grades prioritize stability and downstream compatibility. Shear sensitivity and adsorption are addressed by pump and tubing choice; sterile filtration is validated with pressure and flow budgets that keep topology intact. For storage we avoid cycles that cut supercoiled percentage; 2–8 °C and −20 °C policies are written to match real logistics, not ideal ones.

Where lyophilization is necessary we design and validate cycles with reconstitution behavior as a first-class metric; more often, controlled liquid storage with a disciplined freeze–thaw policy meets the file’s needs. Stability programs include real-time, accelerated, and stress conditions tied to the intended route of use, with acceptance criteria that a scheduler can execute without interpretation.

Regulatory Narrative and Comparability

The Module 3 text begins with QTPP that names the clinical reality, traces that to CQAs measured by the assays above, and declares CPP ranges backed by small, targeted designs and edge-of-failure runs. We front-load the changes that tend to occur—supplier resins, buffer components, scale move, antibiotic-free conversion, backbone clean-up—and attach pre-agreed comparability protocols with acceptance ranges grounded in function. Where lifecycle clarity is useful we borrow from ICH Q12; for banks and identity/safety we map to ICH Q5D; for API-like plasmids we align to ICH Q7 expectations without padding the file. The objective is simple: Plasmid DNA CDMO Services that read like an engineered control strategy, not a scrapbook of successes.

Cost and Throughput Model

COGS is modeled where it actually changes decisions: media/feed costs versus yield and viscosity penalties, antifoam’s real impact on resin lifetime, enzyme use versus validated clearance, buffer volumes balanced against cycle times, and the dollars lost when supercoiled fraction drops below a threshold late in the train. OEE is tracked for fermentors, TFF, columns, and isolators; buffer and media prep capacity is scheduled to avoid hidden bottlenecks. Schedules include buffers that a plant manager believes in February. Savings are not anecdotes; they are line items.

Case Snapshots

1. An IVT-grade program came with a predictable problem: supercoiled fraction unstable after neutralization holds. We mapped the neutralization profile, temperature control, and mixing energy with a three-factor design; changing order of addition and tightening temperature corridors stabilized topology and removed three “hero” interventions per batch. Endotoxin fell because shear and detergent were disciplined upstream; dsRNA excursions in downstream IVT runs disappeared.
2. A GMP plasmid supplying AAV needed endotoxin ≤ 0.01 EU/µg with consistent filterability. We reduced LPS ingress with host choice and growth policy; swapped a legacy detergent for a compatible alternative validated on resin capacity; added an AEX flow-through early and a mixed-mode polish; and validated LER mitigation with a biological orthogonal. Release numbers were boring—the best kind.
3. A sponsor asked for antibiotic-free selection without losing yield. We moved to an auxotrophy-based system, re-balanced feeds to keep specific growth rate under overflow, and confirmed comparability with identity, topology, residuals, and transfection performance. The bridging protocol executed in days, not quarters.

RFP Questions That Separate Signal from Noise

• Show a real QTPP→CQA→CPP map from a plasmid file and the edge-of-failure data that set CPP ranges.
• Provide one soft-sensor validation report with limits of applicability and residual-alarm logic, plus re-qualification cadence.
• Share a completed comparability protocol for an antibiotic-free conversion or resin change and the cycle time.
• Produce an eBR excerpt where lysis was timed by measured signals, not habit, and explain the decision in one paragraph.
• For IVT-grade, show supercoiled fraction and endotoxin across five lots with the same train, and how linearization behaved.

Engagement Model (First 30–60 Days)

Design-to-Proof yields decisions, not curiosity: host and backbone sanity check; feed and µ policy; lysis/neutralization choreography; primary capture selectivity; early polish options; analytics matrix with qualification path; and a draft control strategy. Gene-to-IND or DMF wrap converts that clarity into dossier text, validation plans, and a stability and handling policy that a scheduler and QC can live with. Commercial ramp turns PPQ and CPV on for both classical CQAs and model residuals so drift is caught before it becomes an OOS.

Analytics That Make Conclusions Durable

Identity is a sequence fact, not a branding exercise. Restriction maps remain useful because they catch gross errors quickly, but we treat them as a preamble; the file ties backbone and insert to verified sequence across risk-relevant regions, with coverage expanded where recombination is plausible or when the plasmid is an API, not merely an intermediate. Topology is reported as a distribution—supercoiled, open circular, linear—measured by validated HPLC (ion-exchange or capillary electrophoretic chromatography) and cross-checked by orthogonal gels. We calibrate for size and salt to prevent instrument-driven optimism; acceptance ranges are sized for downstream function (linearization efficiency, transcription productivity), not for résumé aesthetics.

Residuals are not noise; they are the liabilities that make or break downstream performance. Residual host DNA is quantified by qPCR with a method that demonstrates linearity, accuracy, and matrix robustness at the file’s claimed LOQ; the assay reads the species you claim, not a convenient proxy. RNA is measured by RiboGreen or orthogonal methods when RNase-free designs are used; when RNase is admitted, we show clearance with explicit step yields and a residual method with spike recovery that behaves. Host-cell protein is measured by E. coli–specific ELISA or LC–MS fingerprints when panel appropriateness is at issue.

Endotoxin is measured kinetically with appropriate buffering and recovery assessment; if a formulation has a history of LER, we say so and present a biological orthogonal. Residual solvents and detergents are quantified by GC or HPLC with system suitability that survives an audit; conductivity, osmolality, and pH are constrained by ranges tied to the biology of the next unit operation. Bioburden and sterility follow phase; we do not sterilize a development lot into fiction.

Where Plasmid DNA (pDNA) CDMO Services intersect IVT, we add measures that predict transcription reality: percent supercoiled before and after linearization, residual nicked or sheared DNA post-linearization, and a short, controlled IVT demonstrating dsRNA formation within the sponsor’s clearing method bounds. For therapeutic-grade plasmids, we extend analytics into method lifecycle and stability (below) so Module 3 tells a single story.

Stability, Filling, and Control — Engineered for Reality

At Elise Biopharma, we write stability policies from the clinic backward—not from theoretical comfort. Real use defines our limits. If your plasmid must live six months at −20 °C, survive two freeze–thaw cycles, travel on dry ice, and stage for a day at 2–8 °C, that’s what we test and qualify.

We measure what actually fails: supercoiled fraction, residuals, pH, osmolality, clarity, and potency. Real-time and accelerated studies run together so stability reads like physics, not hope. Room-temperature staging? We test it. Freeze–thaw cycles? We exceed them. The outcome is a protocol schedulers can execute and regulators can trust.

Container choice is engineered, not aesthetic. Polypropylene, COC, and COP behave differently under shear, oxygen load, and thaw stress. We qualify each under its real mechanical and thermal conditions—no surprises at 3 a.m. Light sensitivity, extractables, leachables, and label adhesion are validated for the cold chain. The result: a stability plan that needs no improvisation.

Filling and Filtration — Precision in Every Microliter

Plasmid filling is an engineering act, not a routine step. At Elise Biopharma, we preserve topology and sterility with precision. Every fill and filter decision reflects measurable control.

Validated Filtration, Not Assumptions

When filtration is required, we validate it as a process—not a checkbox.
We select membranes that do not bind DNA and run pressure ramps that prevent nicking. Each run confirms recovery by mass balance, not by hope. IVT-grade plasmids use filters compatible with transcription chemistry, while DNA vaccine APIs meet sterile expectations through proven validation, not declarations.

Aseptic Filling with Real Control

Filling occurs in ISO 5 robotic isolators equipped with nitrogen overlays, inline weight checks, and closure integrity verification.
We adjust fill volumes, headspace, and labeling to match real clinical workflows. That means every vial behaves exactly as written—no deviations, no guesswork.

Single-use assemblies dominate our process. When stainless systems are necessary, we document cleaning validation and carryover results explicitly. Everything remains review-ready and regulator-proof.

PPQ and CPV

Validation at Elise is performance, not paperwork. We treat qualification as proof that our Plasmid DNA CDMO Services perform under stress, not comfort.

Process Performance Qualification (PPQ)

PPQ lots run at the edges of proven ranges. We deliberately vary raw-material lots, environmental conditions, and operator shifts.
This demonstrates that the process holds when life happens. Acceptance criteria tie directly to CQAs and capability indices—measured outcomes, not convenient averages.

As a result, our PPQ confirms both capability and confidence before a molecule ever touches the clinic.

Continuous Process Verification

While most CDMOs treat control as a document, Elise turns it into a living system.
Real-time dashboards track CQAs and model residuals, and drift alarms activate long before QC detects a problem.

• Raman signals reveal nutrient shifts before endotoxin rises.
• Chromatography pressure patterns forecast resin fatigue.
• Diafiltration conductivities expose early pH drift before aggregation forms.

Because CPV runs continuously, we correct deviations before they ever exist. It’s control that anticipates, not reacts.

Why It Matters

Most plasmid producers chase compliance. Elise Biopharma designs certainty.
Our integrated stability, filling, and process-control frameworks turn every variable into data and every data point into proof. That’s why our plasmid lots behave predictably, regulators relax during reviews, and programs move from sequence to supply without surprises.
Elise doesn’t meet standards—we set them.

DMF and eCTD Scaffolds

Clarity That Accelerates Approvals

A DMF that confuses reviewers creates delay. We write ours for clarity. Every Plasmid DNA CDMO Services submission is structured for readability and direct cross-referencing, so OEM partners and regulators find what they need fast.

Smart, Structured Sections

• 3.2.S.1 General Information: Plasmid identity, backbone and insert map, origin, copy-number strategy, selection system, and intended use.
• 3.2.S.2 Manufacture: Process flow linked to CPPs; raw material specs with supplier-qualification logic; clear in-process control narratives.
• 3.2.S.3 Characterization: Verified identity, topology, and impurity profiles; rational acceptance criteria tied to downstream use.
• 3.2.S.4 Control of Drug Substance: Validated methods, capability tables, and system-suitability data that prove analytical control.
• 3.2.S.5 Reference Standards: In-house standards with documented stability.
• 3.2.S.6 Container Closure System: Qualified materials with integrity and compatibility data.
• 3.2.S.7 Stability: Protocols, conditions, and acceptance limits aligned with real clinical logistics.

Simplified eCTD Integration

For submissions where plasmid is a component—not a final API—we embed direct cross-references. This prevents duplication and reduces reviewer clarifications.
Every section is concise, verifiable, and written for the reader, not the writer.

Comparability That You Execute, Not Invent, Change Without Chaos

Change is inevitable. At Elise Biopharma, it’s already planned.
We pre-write comparability protocols before scale-up, resin swaps, or antibiotic-free conversions ever occur.
Each protocol defines measurable acceptance criteria:

• Identity and topology equivalence within fixed deltas.
• Residual impurities within risk-ranked ranges.
• Equal transfection performance for AAV or LVV plasmids.
• Matched IVT productivity and dsRNA profiles for RNA templates.

Fast, Pre-Approved Lifecycle Control

Because comparability is part of the plan, bridging studies execute in weeks—not quarters.
We focus on the metrics that move clinical function, not vanity statistics.
Operations never pause to draft memos; they execute tested, regulator-ready protocols. This is how Elise keeps plasmid supply on time even when the world shifts beneath it.

Supply, Risk, and Business Continuity

Reliability by Design

At Elise Biopharma, supply chain assurance is engineered, not improvised.
We qualify all critical inputs—resins, membranes, feedstocks, and contact plastics—under a unified risk framework.
Safety stock matches real consumption and lead times; dual sourcing or tested alternates ensure uninterrupted production.

Operational Resilience

Vendor notifications reach decision-makers instantly through digital change-control triggers. Cold-chain and power systems include redundancy verified by live tests, not promises. Our continuity plans exist in code, not slides.

Transparent Economics

Executives see every lever in real numbers:

Trade-offs of enzyme-free RNA removal.
By pricing variables instead of discovering them, Elise removes surprises from postmortems and replaces them with foresight.

Cost in time and dollars for a resin swap.

Impact of lowering supercoiled thresholds.

Sustainability That Reduces Cost

Solvent recovery and water reuse are not slogans here; they reduce spend and stabilize operations. Buffer recipes are standardized where science allows it; lids are kept on cleaning and contamination control so operators can run faster without cutting corners. Waste routes are sized and documented for actual matrices, not approximations that fail on contact with a manifest. Carbon and utilities are tracked in the historian, tied to agitation, cooling demand, and buffer consumption; managers can read the dashboard and see where a decision saves both carbon and cash.

Our Plasmid DNA Case Studies

Stability under pressure. A sponsor’s IVT-grade plasmid lost supercoiled fraction after staging in a −20 °C freezer shared with other operations. We instrumented real staging behavior, found temperature excursions during door-open cycles, and rewrote the policy: smaller container sizes, staged pulls into a −20 °C buffer box, and a maximum door-open cadence with signage and enforcement. A batch with the same process now maintains supercoiled percentage through staging; IVT runs show dsRNA within spec without extra clearance steps.

Enzyme-free RNA control. A program with RNase sensitivity (downstream) needed RNA removal without the enzyme. We validated a selective precipitation step followed by a mixed-mode polish; the RNA assay went from borderline to consistently below the acceptance limit, and the residual-risk table lost an entire row. Cycle time dropped because we removed an add/hold/wash loop and its cleaning validation tail.

Antibiotic-free conversion on a deadline. A vector program required removal of antibiotic selection ahead of a global trial. Auxotrophy was chosen over toxin–antitoxin for simplicity and dossier clarity. We re-balanced feeds, demonstrated equivalence in copy behavior and filterability, and showed transfection performance equivalence within pre-set deltas. The comparability study executed in eight business days; the IND amendment’s CMC questions were confined to things we had already written.

Vendor resin change. A resin supplier updated ligand density. We ran small-scale columns with the new resin against a matrix of pH, conductivity, and load conditions; the new resin behaved with equal or better capacity and equal selectivity. We adjusted binding and wash windows slightly, wrote a clean protocol addendum, and proceeded. Release and method suitability data supported the swap; the reviewer already had the comparability plan on file.

Analytical & QC Excellence Center

Control is only as strong as the analytics behind it. Elise Biopharma’s Analytical & QC Excellence Center unites molecular biology, biochemistry, and digital QA into a single verification ecosystem that gives regulators confidence and sponsors real-time clarity.

We design analytical strategies that are phase-appropriate, orthogonal, and regulator-aligned from the first pilot batch to commercial supply. Each assay is developed with explicit validation logic so that reproducibility is measurable, not rhetorical.

Core Analytical Services:

• Identity: Full plasmid sequencing with long-read confirmation (ONT/PacBio) and restriction mapping for structural integrity.
• Purity and topology: HPLC, AUC, and CE-SDS quantification of supercoiled (sc), open circular (oc), and linear isoforms with system suitability control.
• Residuals: Host-cell DNA and RNA by qPCR, host-cell proteins by LC–MS and ELISA, endotoxin quantification by kinetic LAL (<0.05 EU/µg typical), and RNase/DNase residuals validated by spike-recovery studies.
• Potency and functionality: In-vitro transcription yield and transfection efficiency testing, ensuring plasmids behave as intended in downstream applications (mRNA, AAV, LVV, or CRISPR).
• Impurity fingerprinting: LC–MS, GC–MS, and ICP–MS profiling of solvents, salts, metals, and excipients to trace even ppm-level liabilities.
• Microbiological quality: Bioburden, sterility, and mycoplasma testing compliant with USP <61>/<62>/<63>.

Comparability & Stability Programs:
We maintain long-term stability protocols per ICH Q5C, mapping every relevant parameter—topology distribution, supercoiled fraction, endotoxin drift, and potency decay—across time and temperature.
Comparability templates are written before process or raw-material changes, ensuring rapid bridging with pre-approved analytical equivalence criteria under ICH Q5E and Q12.

Digital Data Integrity:
All analytical instruments connect directly to Elise’s eBR/MES environment under Part 11-compliant audit trails. System suitability, calibration, and analyst decision logs are visible in real time. This architecture eliminates the interpretive gap between bench data and regulatory review—every value can be traced to a timestamp and a person.

For sponsors, this translates into dossiers reviewers can read without asking for clarifications. For regulators, it means seeing the entire analytical lineage without a single missing link. At Elise Biopharma, analytics isn’t a department—it’s the nervous system of Plasmid DNA CDMO Services.

Linearized & Cell-Free DNA Manufacturing

The next generation of genetic medicines demands cleaner, faster, and more flexible DNA supply. Elise Biopharma’s Linearized & Cell-Free DNA Manufacturing platform answers that need with GMP-grade precision—delivering transcription-ready templates engineered for mRNA, saRNA, circRNA, and synthetic-biology applications.

We approach linear DNA as an engineered intermediate, not a by-product of plasmid digestion. Our workflows integrate enzymatic precision, real-time analytics, and closed-loop digital control to ensure sequence fidelity, complete digestion, and exceptional purity at every scale.

Core Capabilities:

• Enzymatic linearization under control: High-specificity restriction or nicking endonucleases validated for completeness, with residual-enzyme clearance proven by LC–MS and activity assays.
• Cell-free DNA synthesis: Proprietary transcription–translation (TX–TL) modules producing linear constructs directly from template sequences without cellular contaminants; ideal for rapid prototyping and regulated IVT supply.
• Purification architecture: Dual AEX capture + HIC or mixed-mode polish delivering <0.01 EU/µg endotoxin and >98 linear topology purity verified by CE and AUC.
• Analytics integration: In-process PAT for dsDNA integrity via UV/absorbance ratios and temperature-controlled hold profiling to prevent nicking or hydrolysis.
• Digital batch control: Each linearization event and hold step logged in eBR/MES with ALCOA+ traceability for regulatory review.

Applications We Support:

• IVT template production for mRNA, saRNA, and circRNA platforms.
• Gene editing tools requiring linear DNA donors or homology arms.
• DNA vaccines and adjuvant systems needing high copy purity and low residual contaminants.
• Rapid-response manufacturing, where cell-free DNA can be generated within days for emerging pathogens or oncology neoantigen programs.

Why It Matters:
Traditional restriction-based linearization can introduce variability, nick density, and carry-through of enzyme or buffer residues. Elise’s system monitors every variable—enzyme stoichiometry, temperature trajectory, mixing energy, and time at pH—to maintain a validated design space. The result: linear templates with defined integrity and reproducibility across lots, ready for direct use in regulated IVT reactions without additional purification.

Key Advantages of Elise’s Linear & Cell-Free DNA Platform:

• Single-use, closed systems for cross-contamination protection.
• Fast turnaround (72 hours for pre-GMP; <10 days for GMP).
• Scalability from milligram prototypes to multi-gram clinical lots.
• Dual-site production (Cambridge & Montréal) for supply continuity.
• Integrated quality and stability data for IND/IMPD inclusion.

Outcome:
Clients receive linear DNA and cell-free templates that perform exactly as modeled—consistent in length, topology, and biochemical behavior from bench to GMP. Elise Biopharma turns DNA precision into manufacturing certainty, providing the foundation for every modern RNA and gene-editing platform.

Tech Transfer & Lifecycle Support

Moving a plasmid process between labs, sites, or partners can introduce drift. Elise Biopharma’s Tech Transfer & Lifecycle Support framework prevents that drift by translating process knowledge into validated, portable control.

Digital Transfer Packages
Each project ships with a full digital twin—design spaces, CPP–CQA maps, PAT models, and process-response surfaces. These data packages make transfers factual, not interpretive.

Lifecycle Management
We maintain comparability protocols pre-approved under ICH Q5E and Q12. When raw materials, equipment, or scale change, bridging runs execute automatically within defined equivalence limits.

Continuous Process Verification (CPV)
Our CPV dashboards monitor critical attributes in real time. Statistical alarms catch drift long before it reaches release testing.

Optimization & Support
Elise engineers remain embedded through scale-up and commercialization—updating models, retraining soft sensors, and documenting every refinement for regulatory submission.

Benefits

• Predictable tech-transfer timelines and zero revalidation loops.
• Audit-ready comparability evidence for multi-site production.
• Long-term cost control through verified process reproducibility.

Elise turns technology transfer into an engineering hand-off, not a gamble. Every dataset, parameter, and decision travels intact—so your plasmid performs the same way wherever it’s made.

Fill-Finish & Formulation Services

Elise Biopharma completes the plasmid lifecycle with GMP-grade Fill-Finish and Formulation Services that protect integrity through the final step.

We perform aseptic vialing, pre-filled syringe, and cartridge filling in ISO 5 robotic isolators with nitrogen overlays, 100% in-line weight checks, and validated container–closure integrity.

Formulation work focuses on long-term stability: buffer design, lyophilization cycles, cryostorage compatibility, and stress mapping for transport. Whether your plasmid ships frozen, liquid, or dry, we qualify thaw, dilution, and use conditions to keep performance identical at clinic or plant.

Highlights:

• Closed, single-use fill systems preventing cross-contamination.
• Stability studies aligned to ICH Q5C/Q1A.
• Optional lyophilized or cryogenic presentations.
• Packaging validated for −80 °C and 2–8 °C logistics.

Elise doesn’t stop at bulk production—we ensure every vial leaving our suites is stable, sterile, and submission-ready.

Regulatory Consulting & DMF Activation

Elise Biopharma’s regulatory team writes CMC files the way engineers write blueprints—structured, traceable, and built to survive review.

We support IND/IMPD submissions with complete Module 3 text, validation summaries, and process-characterization data aligned to ICH Q5A, Q5E, and Q12. Our experts also prepare and maintain Type II and Type V DMFs, enabling rapid cross-referencing for clients or partners.

Services include:

• Regulatory-gap analysis and dossier harmonization (FDA, EMA, Health Canada).
• Q-sub and scientific-advice support with response drafting.
• Comparability protocols pre-written for lifecycle changes.
• DMF activation and annual maintenance under ALCOA+ governance.

The result: filings that reviewers read once and approve. Elise turns regulatory complexity into clarity, ensuring each plasmid program reaches the clinic—and the market—without delay.

RFP and Diligence

A serious buyer doesn’t need marketing slides—they need evidence.
When evaluating any provider of Plasmid DNA CDMO Services, ask for artifacts that reveal how they actually run.

• Request a QTPP → CQA → CPP map from a completed plasmid program, along with the edge-of-failure data that defined process limits.
• Ask for a soft-sensor validation report showing residual alarms and re-qualification cadence. If they show you a slide instead of a report, it’s not validated.
• Review a comparability protocol for an antibiotic-free conversion or resin swap, including cycle time, results, and deviation closure.
• Read a page of their eBR, confirming that lysis and neutralization timing came from real sensor data—not habit.
• Demand to see five consecutive IVT-grade lots with supercoiled fraction, endotoxin, and RNA profiles so consistent they seem boring.

If a vendor cannot produce those materials, they’re not running a Plasmid DNA CDMO Service—they’re selling optimism.

Elise Biopharma delivers the opposite: measured transparency. Every decision, alarm, and validation step is visible to you, your auditor, and your future reviewer.

Engagement That Delivers Decisions

The first 30–60 days produce decisions, not promises.
You receive a complete risk ledger, strain and backbone sanity check, feed and µ policies, lysis/neutralization choreography, capture and polish strategies, an analytics matrix, and a draft control strategy with PPQ and CPV previews.

By the next quarter, the Gene-to-IND or DMF wrap is complete—validation plans written, stability policy aligned to clinical logistics, and a schedule your operations lead can believe in.
During commercial ramp, we activate PPQ and CPV monitoring for both CQAs and model residuals. Monthly reviews track capability, drift, and confidence. You don’t discover problems at release; you watch them disappear in process.

This is what disciplined Plasmid DNA CDMO Services look like: operational clarity from the first handshake to the final batch.

The Elise Standard — From Sequence to Supply

To treat plasmid DNA as a regulated manufacturing asset is to respect every molecule’s journey from strain to vial. Elise Biopharma’s Plasmid DNA CDMO Services make that respect measurable.
We deliver:

• Identity that’s proven by sequence confirmation, not assumed by heritage.
• Topology that holds under agitation, freeze–thaw, and time.
• Residuals engineered out, not washed out downstream.
• Filling and stability policies written for the operators who will execute them.

Our control strategy is explicit, our validation visible, and our comparability framework pre-written. Before a change occurs, the bridging plan already exists.

When you send Elise your genetic map, intended use, and scale constraints, we return a tangible plan—a route that turns sequence into supply, complete with timelines, acceptance criteria, and dossier text that auditors can follow without interpretation.

Top 10 FAQ: Plasmid DNA Services

1. What differentiates Elise Biopharma’s plasmid DNA CDMO platform from conventional plasmid suppliers?

Most suppliers sell plasmids as research reagents. Elise Biopharma manufactures regulated plasmid DNA as a GMP asset. Every batch is defined by a QTPP → CQA → CPP map, tracked digitally in eBR/MES, and validated with orthogonal analytics.
We apply a unified control system across R&D, HQ, and GMP scales—so analytical signatures, topology ratios, and impurity behavior stay identical from 5 L to 2 000 L. That engineering discipline is why regulators treat Elise as a true plasmid DNA CDMO, not a vendor.

2. How does Elise maintain supercoiled fraction stability during large-scale alkaline lysis?

Supercoiling loss is driven by shear and pH transients. Elise models lysis kinetics with digital twins that monitor conductivity, UV, and temperature in real time.
Neutralization follows a closed-loop control of mixing energy and temperature ramp, preventing over-precipitation and chromosomal DNA shredding. Result: ≥ 95 % supercoiled topology maintained through clarification, verified by HPLC and AUC.

3. What is Elise’s approach to antibiotic-free plasmid manufacturing and regulatory compliance?

We engineer auxotrophy-based or operator–repressor selection systems, replacing antibiotic resistance genes entirely. Each system is validated for plasmid retention, copy number, and growth equivalence to the original construct.
This meets EMA/FDA antibiotic-free expectations and eliminates residual antibiotic and resistance-gene risk in downstream AAV or mRNA manufacturing. It’s cleaner science—and a stronger Module 3 narrative.

4. How low can endotoxin levels be driven, and how is removal proven?

Elise’s endotoxin control is by design, not by detergent. We use low-LPS host backgrounds, gentle harvest and lysis policies, and AEX flow-through steps tuned for real LER behavior.
Residual LPS routinely measures ≤ 0.01 EU µg⁻¹ DNA, verified by kinetic chromogenic LAL and a biological orthogonal. All buffers and resins are validated for endotoxin recovery ≥ 80 %, proving true clearance rather than apparent dilution.

5. Can Elise integrate plasmid analytics with downstream IVT or viral-vector performance data?

Yes. Our Plasmid DNA CDMO Services include functional correlation studies linking plasmid attributes (supercoiled %, residual RNA/DNA, endotoxin, topology variants) to IVT yield and dsRNA formation or AAV vector genome productivity.
This data-fusion approach makes the CMC file defensible—regulators see direct functional evidence that the plasmid’s quality parameters translate to therapeutic performance.

6. How are comparability and lifecycle changes handled for plasmid processes?

All plasmid programs are built with pre-approved comparability protocols under ICH Q5E/Q12.
Whether changing resins, buffers, or converting to antibiotic-free systems, Elise executes bridging studies that measure identity, topology, residuals, and functional performance against statistical equivalence bands.
Because comparability is scripted early, change control runs in weeks—not quarters—without risking filing delays.

7. How does Elise use Process Analytical Technology (PAT) to control fermentation and purification?

PAT is embedded in our reactors and purification skids. Raman/FTIR sensors monitor glucose and acetate; off-gas MS quantifies OUR/CTR; and capacitance probes track viable biomass.
In purification, conductivity and UV signatures forecast column breakthrough. These signals feed digital twins that adjust feed and agitation automatically, maintaining oxygen and heat budgets within proven limits—keeping Plasmid DNA CDMO Services stable lot after lot.

8. What validation standards govern Elise’s analytical and release methods?

Every assay follows ICH Q2(R2). Specificity, linearity (R² ≥ 0.995), accuracy (95–105 %), precision (CV ≤ 10 %), and robustness are documented with system suitability and bracketing.
We maintain traceability for standards and controls under ALCOA+ rules, so reviewers can audit every result to a timestamp and analyst. It’s analytics written for regulators, not for marketing.

9. Does Elise support linearized and cell-free DNA templates for RNA or vaccine production?

Yes. Our Linearized & Cell-Free DNA Manufacturing suite generates IVT-ready templates via enzymatic or cell-free synthesis.
Purity exceeds 98 % linear topology, endotoxin ≤ 0.01 EU µg⁻¹, and residual enzyme activity < LOQ. These templates integrate seamlessly into mRNA and saRNA workflows, providing clients with a one-partner path from plasmid to RNA drug substance.

10. How does Elise guarantee supply assurance and scalability for global clients?

Two mirrored facilities—Cambridge, MA and Montréal, QC—share digital twins, master data, and seed banks under the same QMS.
Critical materials are dual-sourced; cold-chain continuity is tested quarterly; and real-time capacity dashboards manage scheduling across regions.
For clients, this means uninterrupted supply, identical analytics, and a single regulatory language for every site—hallmarks of a world-class Plasmid DNA CDMO.

Closing Thoughts

This is the difference between process and control.
Elise Biopharma doesn’t improvise with plasmid DNA; we industrialize it.
Our Plasmid DNA CDMO Services transform uncertain biology into reliable manufacturing. We write Module 3 files that regulators respect, build processes your engineers can reproduce, and deliver data that reads like truth.

From plasmid design to GMP release, Elise Biopharma makes control a science and quality a certainty.

Email our team directly at info@elisebiopharma.com